Beate wieseler iqwig. wieseler@iqwig.

Beate wieseler iqwig. It is sufficient if the drug is effective and safe. wieseler@iqwig. Beate Wieseler is Head of the Department of Drug Assessment at the German Institute for Quality and Efficiency in Health Care (Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen, IQWiG), Germany’s Health Technology Assessment agency. Mar 3, 2023 · 1 Institute for Quality and Efficiency in Health Care (IQWiG), Cologne, Germany beate. Beate Wieseler's research while affiliated with Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) and other places Mar 2, 2023 · Real world data are advocated as an alternative approach to RCTs for closing knowledge gaps on drugs, but Beate Wieseler and colleagues argue that this approach is the wrong remedy for current challenges in drug development ### Key messages Attempts to accelerate the provision of new treatments have led to evidence that is limited in quantity and quality being submitted for regulatory approval Apr 16, 2025 · Beate Wieseler, Head of IQWiG’s Drug Assessment Department, 04/2025 Patient-reported outcomes (PROs) such as symptoms or health-related quality of life are important criteria for the assessment of cancer drugs. Replacing RCTs with real world data for regulatory decision making: a self-fulfilling prophecy? Jul 10, 2019 · 1 Institute for Quality and Efficiency in Health Care, Cologne, Germany beate. Dr. Beate Wieseler (IQWiG) spricht über das neue EU-HTA-Verfahren und warum transparente Daten, starke Studien und ec Beate Wieseler, Head of IQWiG’s Drug Assessment Department and first author of the article notes: "There are three reasons for the conclusion 'added benefit not proven'. 2 Institute for Quality and Efficiency in Health Care, Cologne, Germany. Innovative trial designs: the EU HTA prespective Beate Wieseler Innovation and Access in Rare Cancers CDDF-EORTC Workshop Amsterdam, 23 September 2024. akonox f2c rezoz1hd zqkubk brk 7sp vttg oh19nq ygrtfjgs zidvln